Journal: Breast Cancer Research : BCR

Article Title: Synergistic lethality of combination treatment with Trop2-directed antibody-drug conjugate sacituzumab govitecan and TRAIL agonists in triple negative breast cancer

doi: 10.1186/s13058-026-02318-4

Figure Lengend Snippet: SG and Apo2L treatment cause cell death through caspase-dependent apoptosis. A , C HCC1806 and MDA-MB-231 cells were treated with SG and Apo2L for 1, 3, 6, 24, 48 and 72 h, respectively. Caspase activation was assessed with a Promega Caspase 3/7 assay. B , D Western blot showing time-dependent effect of SG and Apo2L in HCC1806 (30 nM SG; 1 nM Apo2L) and MDA-MB-231 (73.5 nM SG; 0.7 nM Apo2L), respectively. E Plots of flow cytometry-based annexin V/7-AAD analysis showing fractions of apoptotic cells in MDA-MB-231 and HCC1806 cells. F Quantification of percentages of apoptotic cells in each treatment condition. G , H Cells were pretreated with cell death inhibitors Z-VAD-FMK, necrostatin and ferrostatin for one hour after which SG and Apo2L drugs were added for 24 h to assess cell death rescue. Cell death was measured by propidium iodide-based cell death assay. Statistical significance was determined using Student’s t -test. * indicates p < 0.05, ** indicates p < 0.01 and *** indicates p < 0.001, **** indicates p < 0.0001. Data is shown as average ± SEM of multiple independent experiments ( N ≥ 3)

Article Snippet: Pan-caspase inhibitor Z-VAD-FMK (cat# S7023), necrostatin (cat# S8037), SN-38 (cat# S4908), carboplatin (cat# S1215) were obtained from Selleck Chemicals, and ferrostatin (cat# HY-100579) was from MedChemExpress.

Techniques: Activation Assay, Western Blot, Flow Cytometry